重新定位的simvastatin对二次进展性多发性硬化症 (MS- STAT2) 的残疾进展的影响:一项3期随机双盲,安慰剂对照试验
Jeremy Chataway1, Thomas Williams2, James Blackstone3
1Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK; National Institute for Health and Care Research, University College London Hospitals Biomedical Research Centre, London, UK.
Lancet (London, England)
|October 4, 2025
概括
在MS- STAT2试验中,simvastatin没有减缓二级渐进性多发性硬化症 (SPMS) 的残疾进展. 目前用于多发性硬化症的simvastatin应仅限于已确定的血管指示.
科学领域:
- 神经学
- 临床试验
- 药理学
背景情况:
- 多发性硬化症 (MS) 的残疾进展仍然是一个挑战,可能会因伴随疾病和衰老而加剧.
- 之前的研究 (MS-STAT试验) 表明,simvastatin可以减少SPMS中的大脑缩.
- 这项研究旨在评估simvastatin在减缓SPMS残疾进展方面的疗效.
研究的目的:
- 评估simvastatin与安慰剂在减缓二级渐进性多发性硬化症 (SPMS) 患者的疗效.
主要方法:
- 第3期,随机,双盲,安慰剂对照试验,涉及964名SPMS患者.
- 参与者服用simvastatin (80 mg) 或安慰剂长达4. 5年.
- 主要结果:时间到6个月确认残疾进展 (通过EDSS评估).
主要成果:
- 在simvastatin和安慰剂组之间的残疾进展没有显著差异 (调整后的危险比值为1.13, p=0.26).
- 没有新出现的安全问题,尽管在simvastatin组中发生了一例rhabdomyolysis.
- 在这两组患者中,心血管不良事件很少发生.
结论:
- 在MS- STAT2试验中,simvastatin在减缓SPMS残疾进展方面没有治疗效果.
- 在MS中使用simvastatin应仅限于其现有的血管指示.
- 可能需要进一步的研究来探索其他治疗途径.
相关概念视频
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
253
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
253
01:26Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319